# Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

> **NCT07071103** · PHASE2 · RECRUITING · sponsor: **Chuangzhen Chen** · enrollment: 48 (estimated)

## Conditions studied

- Radiotherapy
- Metastatic Solid Cancers
- Immune Checkpoint Blockade
- Esophageal Neoplasms Malignant
- Lung Neoplasm Malignant
- Drug Resistance

## Interventions

- **RADIATION:** Low-dose radiotherapy to the intestine (ILDR)
- **DRUG:** PD-1/PD-L1 monoclonal antibodies

## Key facts

- **NCT ID:** NCT07071103
- **Lead sponsor:** Chuangzhen Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-26
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07071103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07071103, "Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07071103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*